Skip to main
AXSM

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 53%
Buy 47%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics Inc. demonstrated strong financial performance in the third quarter of 2025, with revenues reaching $136.1 million, surpassing consensus estimates and reflecting a significant 69% year-over-year growth along with a 14% quarter-over-quarter increase. The company's payer coverage showed improvement, increasing to 85%, which bodes well for its revenue sustainability as it continues to expand its market reach through effective contracts and ongoing clinical studies across its pipeline products. Overall, the projections indicate that revenue growth is expected to outpace operating costs, leading to improved operating margins and a potential cash flow positive position by 2026.

Bears say

Axsome Therapeutics Inc. is facing a negative outlook due to a downward revision of its full-year 2025 revenue forecast to $628.3 million, indicating potential challenges in achieving past projections. Key risks impacting its operations include concerns regarding market access for AUVELITY, setbacks in clinical trials for AXS-05 and other candidates, and the possibility of lower-than-expected commercial success attributed to competition and market penetration issues. Additionally, the company faces the potential for long-term dilution risks, which could further undermine investor confidence and financial stability.

Axsome Therapeutics (AXSM) has been analyzed by 17 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 47% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 17 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.